Warning letter
Abbott Laboratories, Inc.: warning letter of Sep 24, 2002
FDA warning letter UCM145123 · Chicago District Office
Key facts
| Reference number | UCM145123 |
|---|---|
| Company | Abbott Laboratories, Inc. |
| Subject | Current Good Manufacturing Practices for Finished Pharmaceuticals/Adulterated |
| Issue date | Sep 24, 2002 |
| Posted date | Sep 24, 2002 |
| Issuing office | Chicago District Office |
| Product type | Drugs |
| CFR sections cited | 211.67(a), 211.192, 211.100(a) |
| Country | 3 |
| Inspection city | Abbott Park |
| Inspection ZIP | 60064-3502 |
| Inspection start date | Jun 18, 2002 |
| Letter on fda.gov | web.archive.org |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: